MUC1 and colonic neoplasm: A Mucin (MUC1)-based vaccine was employed in a preclinical model of colon cancer by Mukherjee et al. MC38 colon cancer cells, expressing MUC1, were put into immune-competent MUC1-tolerant hosts, who were then given the vaccination.